Clinical Researcher—June 2026 (Volume 40, Issue 3)
ON THE JOB
Tejashree Kulkarni, MS
In clinical research, terminology directly affects compliance, patient safety, and data integrity. At the site level, commonly misunderstood terms can result in protocol deviations, delayed safety reporting, billing errors, and inspection findings. This article reviews frequently confused clinical trial terms and explains their operational and regulatory implications, with reference to the International Council for Harmonization (ICH) guideline for Good Clinical Practice (GCP) and U.S. Food and Drug Administration (FDA) guidance. Clear and consistent interpretation of these terms is essential for maintaining inspection readiness and ensuring high-quality study execution.
Background
Clinical trials depend on consistency, accuracy, and adherence to regulatory standards. While processes are often emphasized, terminology plays an equally important role in trial conduct. Many commonly used clinical research terms appear similar but have distinct regulatory meanings. Misinterpretation at the site level can lead to reporting delays, compliance gaps, and data integrity issues. Frameworks such as the ICH GCP guideline and regulatory guidance from the FDA provide standardized definitions. However, operational variability across sponsors and sites continues to create inconsistency in application.
Here are some of the most important terms and definitions, along with associated site impacts and other considerations, that clinical research professionals should familiarize themselves with as early in their exposure to the drug and device development industry as possible:
Adverse Event (AE) vs. Serious Adverse Event (SAE)
An Adverse Event (AE) is any untoward medical occurrence in a participant administered a study intervention, regardless of causality.
A Serious Adverse Event (SAE) is defined by outcome and includes events that:
- Result in death
- Are life-threatening
- Require or prolong hospitalization
- Result in persistent or significant disability/incapacity
- Are medically important
(ICH E6(R3), Section 2.7; FDA Safety Reporting Guidance)
Site Impact
SAEs require expedited reporting to sponsors and sometimes regulatory authorities. Misclassification can result in:
- Missed reporting timelines
- Protocol noncompliance
- Inspection findings
Accurate and timely classification is essential for participant safety oversight and regulatory compliance.
Reporting Timelines and Regulatory Expectations
SAEs must be reported to sponsors immediately or within timelines specified by the protocol—often within 24 hours of site awareness. Sponsors are then responsible for determining whether the event requires expedited reporting to regulatory authorities.
Under FDA safety reporting requirements (21 CFR 312.32 in the Code of Federal Regulations), sponsors must notify the FDA and investigators when an adverse event is both serious and unexpected and there is reasonable evidence suggesting the study drug caused the event.
Typical FDA expedited reporting timelines include:
- 7 calendar days for fatal or life-threatening unexpected suspected adverse reactions
- 15 calendar days for other serious and unexpected suspected adverse reactions
Failure to meet reporting timelines may result in:
- Regulatory findings
- Delayed safety signal detection
- Increased inspection scrutiny
- Potential risks to participant protection
Suspected Unexpected Serious Adverse Reaction (SUSAR)
This is a specific type of safety event in clinical trials that requires expedited regulatory attention because it may represent a new or significant risk associated with the investigational product. A SUSAR must meet all three of the following criteria:
Serious
- Results in death
- Is life-threatening
- Requires/prolongs hospitalization
- Causes significant disability/incapacity
- Causes congenital anomaly
- Or is otherwise medically important
Unexpected
- The event is not consistent with known risks described in the:
- Investigator’s Brochure
- Package insert
- Protocol safety information
Suspected
- There is a reasonable possibility that the investigational product caused the event.
Why Do SUSARs Matter?
SUSARs are important because they may indicate:
- A newly identified safety risk
- A change in the study’s risk-benefit profile
- The need for:
- expedited FDA reporting,
- investigator notifications,
- protocol amendments,
- consent form updates,
- or additional safety monitoring.
Reporting Timelines
Under FDA regulations:
- Fatal or life-threatening SUSARs are generally reported within 7 calendar days
- Other SUSARs are reported within 15 calendar days
Screening Failure vs. Screen Failure Costs
A screen failure refers to a participant who signs informed consent but is not enrolled due to not meeting eligibility criteria.
Confusion often arises when determining billing responsibility for screening procedures, particularly in distinguishing:
- Standard of Care procedures
- Research-specific procedures
(FDA Clinical Trial Billing Compliance Guidance; Centers for Medicare & Medicaid Services Clinical Trial Policy)
Site Impact
Incorrect classification may result in:
- Billing noncompliance
- Sponsor payment disputes
- Financial loss for the site
Clear coverage analysis is required to ensure appropriate allocation of costs and avoid compliance risks.
Protocol Deviation vs. Protocol Violation
Definitions vary by sponsor, but generally:
- Protocol Deviation: Minor departure from protocol procedures without significant impact on safety or data integrity
- Protocol Violation: More significant noncompliance potentially affecting subject safety
Site Impact
Inconsistent classification may lead to:
- Inaccurate reporting to sponsors/institutional review boards
- Documentation inconsistencies
- Increased inspection scrutiny
Sites must follow sponsor-specific definitions while maintaining consistent internal documentation practices.
Source Data vs. Source Documentation
- Source Data: Original clinical observations or measurements
- Source Documentation: The medium where source data are recorded
Site Impact
Discrepancies between source data and documentation can compromise data integrity. Regulatory expectations require adherence to ALCOA principles:
- Attributable
- Legible
- Contemporaneous
- Original
- Accurate
Inconsistent documentation may lead to monitoring findings or inspection observations related to data reliability.
Enrollment vs. Randomization
- Enrollment: Participant signs informed consent
- Randomization: Participant is assigned to a study arm
Site Impact
Confusing these milestones can lead to:
- Overstated recruitment metrics
- Misaligned sponsor reporting
- Inaccurate feasibility projections
Clear separation is necessary for accurate trial tracking and performance assessment.
Real-World Inspection Scenario: Why Terminology Matters
During a routine regulatory inspection at a multisite study, inspectors identified inconsistencies in adverse event classification across patient records. At one site, events requiring overnight hospitalization were documented as AEs rather than SAEs due to internal misunderstanding of severity criteria.
Further review revealed that:
- SAE reporting timelines were not consistently triggered
- Sponsor safety reports contained delayed submissions
- Training records did not clearly differentiate AE vs. SAE criteria
The inspection resulted in multiple observations related to:
- Inadequate safety reporting procedures
- Inconsistent application of protocol definitions
- GCP noncompliance in documentation practices
Key Learning
This scenario highlights how terminology misinterpretation can escalate into systemic compliance issues. The root cause was not lack of reporting activity, but inconsistent understanding of definitions across site staff.
Broader Compliance Implications
Misunderstanding clinical trial terminology can lead to:
- Delayed safety reporting
- Billing compliance issues
- Documentation inconsistencies
- Data integrity concerns
- Inspection findings
Regulatory authorities expect sites to demonstrate consistent application of protocol and regulatory definitions across all study processes.
Strategies to Reduce Risk
- Develop site-level reference materials aligned with ICH GCP and sponsor-specific guidance.
- Include scenario-based training focused on AE/SAE classification, deviations, and billing principles.
- Confirm definitions during initiation to avoid variability in interpretation.
- Ensure alignment across source documents, case report forms, and regulatory files.
- Incorporate terminology accuracy into internal audits and quality management systems.
Conclusion
Clinical trial terminology directly impacts compliance, patient safety, and data integrity. While frameworks such as the ICH GCP guideline and FDA guidance provide clear definitions, variability in interpretation at the site level remains a persistent risk. Strengthening terminology understanding through training, standardization, and sponsor alignment can significantly reduce operational errors and improve inspection readiness.
Resources
- International Council for Harmonization. 2025. ICH E6(R3): Guideline for Good Clinical Practice.
- U.S. Food and Drug Administration. 2012. Guidance for Industry: Safety Reporting Requirements for INDs and BA/BE Studies.
- U.S. Food and Drug Administration. 2013. Use of Electronic Source Data in Clinical Investigations: Guidance for Industry.
- Centers for Medicare & Medicaid Services (CMS). 2000. Clinical Trial Policy (NCD 310.1).
Tejashree Kulkarni, MS, is a Clinical Trial Manager with experience in site-level clinical research operations, including study start-up, feasibility, budgeting, regulatory compliance, and day-to-day trial conduct. Her experience spans coordination of multidisciplinary study teams and support of regulatory inspections and sponsor audits. She is focused on improving clinical trial quality and operational consistency through practical application of Good Clinical Practice principles.
